Atea Pharmaceuticals

Atea Pharmaceuticals, Inc. is a clinical stage company, which focuses on discovering, developing, and commercializing antiviral therapeutics. Its product pipelines include Coronaviridae, Flaviviridae, and Paramyxovirdae. The company was founded by Jean-Pierre Sommadossi and David Chu in July 2012 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Atea Pharmaceuticals advances COVID-19 treatment, diversifies programs for growth

Atea Pharmaceuticals showcased strong performance in clinical development and financial stability, with a focus on addressing COVID-19 therapy limitations.
While challenges exist in deprioritizing the Dengue program, opportunities in other antiviral programs and strategic shifts offer avenues for growth.
The company's extended cash guidance to 2026 reflects adaptability to changing priorities and a commitment to long-term success.

Atea Pharmaceuticals excels in Q1 2023, poised for growth

Atea Pharmaceuticals demonstrated strong financial performance and progress in their COVID-19 and HCV programs in Q1 2023.
The company's robust cash balance, operational excellence, and promising drug profiles highlight their competitive position.
While facing challenges in regulatory environments and clinical trial execution, Atea has opportunities for growth and market expansion.
Overall, Atea Pharmaceuticals remains well-positioned for future success with a focus on innovation and strategic partnerships.

Atea Pharmaceuticals reports strong Q2 earnings, eyes growth in antiviral treatments

Atea Pharmaceuticals demonstrated financial stability and progress in their antiviral programs, particularly in COVID-19 and hepatitis C treatments. While challenges with COVID-19 mutations persist, the company's focus on innovative treatments and potential partnerships signal a promising future in the antiviral market.

Atea Pharmaceuticals excels in antiviral programs, eyes multibillion-dollar market

Atea Pharmaceuticals demonstrated strong performance in Q3 2023, leveraging their expertise in antiviral therapeutics to address critical healthcare challenges. While challenges such as trial enrollment and market competition exist, the company is well-positioned to capitalize on the growing demand for innovative antiviral treatments.

Atea Pharmaceuticals excels in drug development, eyes growth opportunities

Atea Pharmaceuticals is making significant strides in drug development, particularly in COVID-19 and HCV programs. With a strong financial position and a focus on addressing unmet medical needs, the company is poised for future growth and success.

Atea Pharmaceuticals reports robust Q1 earnings, highlights bemnifosbuvir potential

Atea Pharmaceuticals showcased strong financial stability and promising developments in its COVID-19 and HCV programs during the Q1 2024 earnings call. While facing challenges in trial enrollments and regulatory pathways, the company remains well-positioned to capitalize on market opportunities and deliver value through innovative treatments.

Atea Pharmaceuticals reports strong Q2 earnings and advances HCV treatments

Atea Pharmaceuticals is well-positioned with strong operational performance, a promising HCV treatment pipeline, and a solid financial foundation. Navigating industry competition and successfully advancing Phase III trials will be key challenges, but the company has opportunities to solidify its position as a leader in HCV treatment.

Atea Pharmaceuticals excels in Q3 with promising HCV program

Atea Pharmaceuticals demonstrated strong performance in Q3 2024, with promising trial results and a solid financial position.
The company's HCV program shows great potential for addressing unmet medical needs and driving future growth.
While facing challenges in trial design and market competition, Atea remains confident in its ability to innovate and succeed in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for the treatment of HCV. These data are being presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Jonae Barnes - SVP of Investor Relations and Corporate Communications Dr. Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Dr. Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Dr. Arantxa Horga - Chief Medical Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Isabella Camaj - JPMorgan Andy Hsieh - William Blair Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Atea Pharmaceuticals, Inc. (AVIR) Q3 2024 Earnings Call Transcript

Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4'24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases' (AASLD's) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir to be Presented at American College of Pharmacometrics Meeting Conference Call at 4:30 pm ET Today BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a business update. “We continue to make significant progress in our HCV program with the combination of bemnifosbuvir and ruzasvir, which has a potential best-in-class profile.

Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2024 in San Diego, CA.

Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024

Here is how Atea Pharmaceuticals, Inc. (AVIR) and Doximity (DOCS) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?

Clipper Realty

Harmony Gold Mining Co Ltd

REE Automotive Ltd

Westport Fuel Systems

CLPR, REE, HMY, AVIR and WPRT have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2024.

New Strong Buy Stocks for October 16th

Atea Pharmaceuticals (AVIR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here is how Atea Pharmaceuticals, Inc. (AVIR) and PetIQ (PETQ) have performed compared to their sector so far this year.

Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?

BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. In SUNRISE-3, bemnifosbuvir was generally safe and well tolerated.

Atea Pharmaceuticals Provides Update on Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19

New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses New Data Further Elucidates Bemnifosbuvir's Metabolic Activation Pathway, Critical to its Mechanism of Action as an Antiviral Therapy for Treatment of COVID-19, HCV and Potentially a Broad Range of RNA Viruses

Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir's Metabolic Activation Pathway

Atea Pharmaceuticals (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Atea Pharmaceuticals (AVIR) Rating Upgrade to Buy

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Second Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Atea Pharmaceuticals, Inc. (AVIR) Q2 2024 Earnings Call Transcript

BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business update.

Atea Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call on August 7, 2024

BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York.

Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference

Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial

Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jonae Barnes - Senior Vice President of Investor Relations and Corporate Communications Jean-Pierre Sommadossi - Founder and Chief Executive Officer Arantxa Horga - Chief Medical Officer Janet Hammond - Chief Development Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - Chief Financial Officer and Executive Vice President of Legal Conference Call Participants Maxwell Skor - Morgan Stanley Jonathan Miller - Evercore ISI Tim Lugo - William Blair Rosa Chen - Leerink Partners Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals First Quarter 2024 Financial Results and Business Update Conference Call. At this time, all participants are in listen-only mode.

Atea Pharmaceuticals, Inc. (AVIR) Q1 2024 Earnings Call Transcript

BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the presentation of Phase 1 data highlighting the safety profile of bemnifosbuvir, an oral nucleotide polymerase inhibitor, at the European Society of Clinical Microbiology & Infectious Diseases Global 2024 (ESCMID, formerly ECCMID), which is taking place April 27-30, 2024 in Barcelona, Spain.

Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024

Enrollment Reached Over 2,200 High-Risk Patients in Bemnifosbuvir Monotherapy Cohort Results from SUNRISE-3 Expected in 2H'24 BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort and less than 80 patients were randomized into the combination cohort.

Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients

Atea Pharmaceuticals, Inc. (AVIR) Q4 2023 Earnings Call Transcript

Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update.

Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.

Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study

A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study

Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 10:30 a.m. PT in San Francisco, CA.

Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

First Clinical Data for Coadministration of Bemnifosbuvir and Ruzasvir Show Combination Was Well Tolerated in a Phase 1 Study

Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023

News for Atea Pharmaceuticals Stock (AVIR)